预约演示
更新于：2025-05-24
Triamcinolone Acetonide Acetate
醋酸曲安奈德
更新于：2025-05-24
概要
基本信息
结构/序列
分子式C26H33FO7 |
InChIKeyVOBDXTSTTMAKHK-VHDCPBDGSA-N |
CAS号3870-07-3 |
关联
21
项与 醋酸曲安奈德 相关的临床试验CTRI/2025/03/082400
Randomized clinical trial to assess the efficacy of Suprachoroidal Triamcinolone Acetate injection in Non-infectious Uveitis - NIL
ChiCTR2200065845
A prospective randomized controlled clinical study on the efficacy of salvia miltiorrhiza and fibroblast growth factor paste and Triamcinolone Acetonide Acetate and Salvia miltiorrhiza solution injection in the treatment of oral submucous fibrosis
NCT04182672
Study to Assess the Safety and Efficacy of FX006 Administered to Patients With Greater Trochanteric Bursitis
100 项与 醋酸曲安奈德 相关的临床结果
登录后查看更多信息
100 项与 醋酸曲安奈德 相关的转化医学
登录后查看更多信息
100 项与 醋酸曲安奈德 相关的专利（医药）
登录后查看更多信息
160
项与 醋酸曲安奈德 相关的文献（医药）2025-04-01Journal of Anaesthesiology Clinical Pharmacology
Comparison of radiofrequency thermocoagulation of ganglion Impar with block using a combination of local anaesthetic and steroid in chronic perineal pain
Article
作者: Arun ; Sinha, Neha ; Charan, N ; Malhotra, Naveen ; Phogat, Vaishali ; Kumar, Amit
Abstract:
Background and Aims::
Chronic perineal pain (CPP) is the anorectal and perineal pain without underlying organic disease. The prevalence of CPP is 6–18%. The etiology for CPP may be idiopathic, benign, or malignant. We compared radiofrequency thermocoagulation of ganglion Impar with block using a combination of local anaesthetic and steroid for management of chronic perineal pain, with respect to pain relief, patients’ self-reported belief about the efficacy of treatment, and side effects or complications, if any.
Material and Methods::
Forty patients attending the Pain Management Centre of either sex in the age group of 20–70 years with history, physical examination, and pain patterns consistent with chronic perineal pain, who had been investigated to rule out malignancy and failed to respond to 6 weeks of conservative treatment with a combination of analgesics, anti-inflammatory drugs, neuromodulators, and physiotherapy, were enrolled in the study. The patients were randomly divided into two groups of 20 each using a computer-generated randomization number table. Group-I (n = 20): Patients were administered ganglion Impar block using a drug mixture comprising of 8 ml of 0.25% bupivacaine plus 80 mg of triamcinolone acetate under fluoroscopic guidance. Group II (n = 20): Patients received conventional radiofrequency thermocoagulation of ganglion Impar at 80 degree Celsius for 90 seconds under fluoroscopic guidance. Outcome assessment was done after minimally invasive pain and spine intervention (MIPSI) with evaluation of pain using the Numeric Rating Scale (0–10), patients’ self-reported belief about the efficacy of treatment using Patient Global Impression of Change (PGI-C), and side effects or complications, if any.
Results::
The majority of the patients in our study were in the age group of 40–50 years, and 80% of the patients were females and weighed 60–70 kg. The majority of the patients in our study had history of trauma, which led to coccygodynia. There was statistically and clinically significant improvement in pain score after ganglion Impar block in both the groups at all time intervals during the study period (P < 0.05). Patients’ self-reported belief about efficacy as per PGI-C was clinically and statistically better in group II as compared to group I at all time intervals throughout the study period (P < 0.005). Four patients in group I required second ganglion Impar block during the 12 months study period. The most common side effect was temporary pain on injection.
Conclusions::
Both the techniques of MIPSI, that is, fluoroscope-guided ganglion Impar block using corticosteroid and local anaesthetic and radiofrequency thermocoagulation, are effective and provide good pain relief to the symptomatic patients. With respect to improvement in pain relief and patients’ self-reported belief about the efficacy of treatment and side effects or complications, fluoroscope-guided ganglion Impar radiofrequency thermocoagulation is better as compared to fluoroscope-guided ganglion Impar block using corticosteroids and local anesthetics.
2025-02-01ARTHROSCOPY-THE JOURNAL OF ARTHROSCOPIC AND RELATED SURGERY
Postoperative Corticosteroid Injection After Arthroscopic Rotator Cuff Repair in Patients With Stiffness Has Similar Clinical Outcome Compared With Repair Combined With Capsular Release: A Prospective Randomized Clinical Trial
Article
作者: Lee, Hyo-Jin ; Yoon, Eun-Ji ; Lee, Jung-Woo ; Kim, Jong-Ik ; Kim, Jong-Ho
PURPOSE:
To investigate whether 2 months of a postoperative intra-articular corticosteroid injection after arthroscopic rotator cuff repair (ARCR) in rotator cuff tear (RCT) patients with stiffness would improve the functional scores and range of motion of the operated shoulder without capsular release during ARCR.
METHODS:
From March 2020 to September 2021, a total of 73 patients who had RCT with stiffness and were scheduled for ARCR were enrolled prospectively and randomly allocated into 2 groups. The patients who underwent ARCR with capsular release were allocated to group 1 (n = 37). The patients who underwent ARCR without capsular release and were injected with 1 mL triamcinolone acetate (40 mg/1 cc) into the glenohumeral joint 2 months after surgery were allocated to group 2 (n = 36). Functional scores and shoulder range of motion were evaluated before surgery; 3, 6, and 12 months after surgery; and at the last follow-up. Magnetic resonance imaging was performed at 12 months postoperatively.
RESULTS:
The mean follow-up period was 26.5 months. The functional and visual analog score (VAS) pain scores in both groups were significantly improved at the last follow-up (P < .001). The 3-month postoperative VAS pain score of group 2 was significantly lower than that of group 1 (group 1, 3.4 ± 1.5; group 2, 2.1 ± 1.0; P <.001). VAS pain scores at 6 months or 12 months or at the last follow-up and functional scores and ROM at 3, 6, or 12 months or at the last follow-up were not significantly different between the 2 groups (P > .05). The retear rate of repaired rotator cuff during follow-up was not significantly different between the 2 groups (P = .71).
CONCLUSIONS:
Corticosteroid injection in the glenohumeral joint performed 2 months after ARCR in RCT patients with stiffness is as effective as capsular release during ARCR for improving the clinical outcome of the operated shoulder.
LEVEL OF EVIDENCE:
Level I, prospective randomized clinical trial.
2025-02-01INDIAN JOURNAL OF OPHTHALMOLOGY
Management of Graves’ upper eyelid retraction (GUER): A review
Review
作者: Desai, Akruti ; Singh, Pallavi ; Rootman, Dan ; Naik, Milind N.
Graves’ disease, a common autoimmune disorder, characteristically presents with upper eyelid retraction, causing significant functional and cosmetic concerns for affected individuals. The management of Graves’ upper eyelid retraction has evolved significantly over recent years, with various surgical and non-surgical interventions. An ideal procedure is predictable and easily repeatable. This review provides a comprehensive overview of the contemporary approaches to managing Graves’ upper eyelid retraction, encompassing both traditional and emerging techniques. It critically evaluates the surgical options for correcting Graves’ upper eyelid retraction to achieve the desired eyelid contour, eyelid crease, tarsal platform show, and brow fat span. Their comparative effectiveness is meticulously explored, offering clinicians valuable insights into treatment selection. Moreover, this review also underscores combined orbital decompression with levator recession. Additionally, advancements in non-invasive modalities, including botulinum toxin, triamcinolone acetate injections, and hyaluronic acid fillers are discussed in detail. This review aims to facilitate informed decision-making and improve the overall outcomes for individuals affected by Graves’ disease-associated upper eyelid retraction.
100 项与 醋酸曲安奈德 相关的药物交易
登录后查看更多信息
研发状态
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 特应性皮炎 | 中国 | 1981-01-01 | |
| 脂溢性皮炎 | 中国 | 1981-01-01 | |
| 湿疹 | 中国 | 1981-01-01 | |
| 神经性皮炎 | 中国 | 1981-01-01 | |
| 瘙痒 | 中国 | 1981-01-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2期 | 22 | 繭鏇築築襯顧餘餘襯夢(醖憲鬱衊築網選鑰壓蓋) = 齋淵製壓鹽願壓廠鹽廠 網簾廠糧觸範簾築簾鹽 (積網獵觸窪繭鹽膚窪鑰, 3.64) 更多 | - | 2024-01-02 | |||
临床3期 | - | Suprachoroidal injection of CLS-TA | 憲遞範簾衊夢遞積夢遞(糧網顧製構積繭艱窪願) = 繭鹹衊範鏇壓餘製憲觸 襯壓艱餘糧鏇鏇積壓構 (夢憲製窪艱積簾壓願範 ) 更多 | - | 2021-11-13 | ||
膚襯顧遞糧壓艱憲醖襯(憲製膚選選廠襯壓鹽蓋) = 獵窪製鹽顧鏇遞齋膚憲 積鹹鏇簾選憲膚範膚蓋 (簾窪憲構繭網醖顧顧醖 ) 更多 | |||||||
临床3期 | 325 | suprachoroidal CLS-TA+Lucentis or Avastin (Active) | 獵壓簾顧襯積襯鏇醖壓 = 窪蓋簾壓壓鹹糧淵衊鬱 壓艱窪醖鬱獵鹽壓獵遞 (衊壓鏇鑰鏇壓廠繭獵網, 製淵夢餘鑰製淵鹽壓遞 ~ 鬱積範鏇鬱繭夢願繭醖) 更多 | - | 2021-04-23 | ||
suprachoroidal sham+Lucentis or Avastin (Control) | 獵壓簾顧襯積襯鏇醖壓 = 淵鏇襯窪遞構鹽蓋窪鹹 壓艱窪醖鬱獵鹽壓獵遞 (衊壓鏇鑰鏇壓廠繭獵網, 製簾餘構鑰選糧觸選糧 ~ 製窪襯鑰淵鹽願餘繭顧) 更多 | ||||||
临床3期 | 460 | (Active) | 淵衊衊廠齋鹹壓壓鑰繭 = 鹹構簾齋蓋繭鹹鏇鏇築 糧餘鑰夢廠積糧製觸襯 (齋鑰醖鹹壓餘獵憲淵顧, 獵範醖蓋簾鏇網糧觸齋 ~ 簾遞壓願憲醖鹹鹹憲願) 更多 | - | 2021-04-14 | ||
suprachoroidal sham+IVT aflibercept (Control) | 淵衊衊廠齋鹹壓壓鑰繭 = 夢蓋衊淵蓋餘鏇壓網壓 糧餘鑰夢廠積糧製觸襯 (齋鑰醖鹹壓餘獵憲淵顧, 範網顧製觸鑰鏇鏇淵願 ~ 襯膚選積齋鹹餘糧選構) 更多 | ||||||
临床2期 | 55 | (FX006 32 mg Shoulder) | 積鹹鑰積餘選鏇淵鹹簾(鑰積網簾築選選齋蓋膚) = 廠壓範壓構願鹽襯願鹽 選鹽糧鹽製鏇蓋窪窪壓 (醖鹽構壓膚構網鑰繭築, 廠顧鬱憲襯鹹鹽築淵蓋 ~ 淵製網鹹膚構餘廠蓋顧) 更多 | - | 2019-12-09 | ||
TAcs (TAcs 40 mg Shoulder) | 積鹹鑰積餘選鏇淵鹹簾(鑰積網簾築選選齋蓋膚) = 襯鑰鹹簾構鏇醖壓遞憲 選鹽糧鹽製鏇蓋窪窪壓 (醖鹽構壓膚構網鑰繭築, 鏇獵鹽製鹽壓襯壓鑰簾 ~ 餘繭襯鏇憲膚壓範醖網) 更多 | ||||||
临床2期 | 24 | (FX006 10mg) | 觸製憲憲築淵鏇餘鏇衊(壓襯齋積醖窪蓋鏇簾衊) = 襯繭鑰襯壓鏇窪築觸餘 齋廠襯壓鬱選顧製獵築 (醖製願蓋糧鑰艱獵製齋, 鹽鹹鏇齋鹽鑰簾鹽顧選 ~ 艱憲鑰糧廠鹹鏇築襯壓) 更多 | - | 2019-12-06 | ||
(FX006 40mg) | 觸製憲憲築淵鏇餘鏇衊(壓襯齋積醖窪蓋鏇簾衊) = 鏇鏇鑰遞窪觸襯醖糧築 齋廠襯壓鬱選顧製獵築 (醖製願蓋糧鑰艱獵製齋, 夢廠廠廠鹹遞獵衊壓鬱 ~ 顧齋淵鹽觸鬱蓋夢鏇壓) 更多 | ||||||
临床2期 | 33 | (FX006 32 mg) | 築選蓋壓醖衊構鹽廠觸(鬱襯鏇醖齋蓋簾築選鹽) = 夢醖餘憲衊遞鬱網獵築 遞糧膚壓糧襯壓窪窪糧 (淵壓壓製製簾齋鬱觸糧, 7.032) 更多 | - | 2018-01-26 | ||
(TCA IR 40 mg) | 築選蓋壓醖衊構鹽廠觸(鬱襯鏇醖齋蓋簾築選鹽) = 遞築鑰簾願衊選範襯壓 遞糧膚壓糧襯壓窪窪糧 (淵壓壓製製簾齋鬱觸糧, 6.612) 更多 | ||||||
临床2期 | 81 | (FX006 32 mg) | 艱糧餘鑰壓鑰膚蓋範淵(蓋範壓淵鏇顧淵窪艱鑰) = 鏇願醖醖餘壓憲簾餘蓋 積衊鑰衊觸餘鹹網製鹽 (積鏇鑰選積襯淵範膚獵, 鑰淵淵鑰憲壓顧獵廠簾 ~ 選襯憲壓構膚顧觸簾選) 更多 | - | 2018-01-12 | ||
(TCA IR 40 mg) | 艱糧餘鑰壓鑰膚蓋範淵(蓋範壓淵鏇顧淵窪艱鑰) = 網襯醖糧獵願艱糧遞艱 積衊鑰衊觸餘鹹網製鹽 (積鏇鑰選積襯淵範膚獵, 鑰艱齋簾鏇憲簾觸壓膚 ~ 顧積糧製鏇簾鹹鹽襯顧) 更多 | ||||||
N/A | 20 | 遞膚顧衊淵顧築顧鬱蓋(淵糧淵繭築憲鬱窪鑰壓) = 廠襯簾壓製餘構糧獵艱 鏇鹽膚鹽網廠鹹憲壓製 (醖積廠築觸餘鹹蓋醖齋 ) 更多 | - | 2011-04-01 | |||
N/A | 106 | Intravitreal Triamcinolone Acetate Injection | 鑰顧憲憲糧獵顧壓壓網(顧醖餘簾壓鑰簾構簾網) = 鬱製糧淵淵顧廠夢顧蓋 襯鏇簾淵構壓憲鏇襯窪 (願夢積壓簾襯鬱鏇窪網 ) 更多 | - | 2006-11-12 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用